Aslan Pharmaceuticals Ltd ADR (ASLN) Stock Price, Quote & News

Stormra Aug. 26 at 6:02 PM

$ASLN I just got this....

1 · Reply

HPgambler Aug. 19 at 12:32 PM

$ASLN have they went completely bankrupt? What’s the latest news? This is glitching my Robinhood account and showing me down $725 every single day, Robinhood said they can’t remove it because they are still working on compliance but it has been froze forever. I am just tired of my account looking like I’m down every single day. Oh and there is a kicker, it switches on Robinhood randomly so I jump back and forth from $725 down to whatever my true position is on all my other investments.

1 · Reply

PLATINUM_TRADES Aug. 8 at 12:17 PM

$ASLN hello.. Anyone in here? What is going on here😑

0 · Reply

GhostAlphaTrading Jun. 17 at 12:08 PM

$ASLN Is this delisted??

1 · Reply

TrdrBuckNKy Apr. 17 at 2:05 PM

$ASLN News 15/04 08:02 ASLAN PHARMACEUTICALS LTD HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ: ASLN) with a Buy and maintains $9 price target.

1 · Reply

redfox43202 Jan. 19 at 10:36 PM

$ASLN Got charged again for ADR fees on 1/14. God damn it. What a curse to own this shit. How many times have we been charged for nothing?

0 · Reply

GhostAlphaTrading Dec. 6 at 11:22 AM

$ASLN ......can't even put a sell order in or a buy what's going on..

0 · Reply

goodetrades Nov. 19 at 2:47 PM

$ASLN If anyone is tired of waiting for something to happen, I would be happy to buy your shares from you at $0.60 (the close on the last trading day). DM me for details. I'm short and while I'm not paying very expensive borrow I would like to clear this off my books and move on.

2 · Reply

10BillyBioBearBruiser Nov. 13 at 4:37 PM

$ASLN What a call 🫡 Well take your word for $ALT

1 · Reply

SQUEAKSBANDIT Nov. 8 at 12:56 AM

how many shares do you guys have i have 1k @ .60 $ASLN

3 · Reply

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

CERO

Jul 17, 2024, 7:25 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

Jul 15, 2024, 7:30 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

May 21, 2024, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

May 9, 2024, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:30 AM EDT - 1 year ago

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

May 2, 2024, 9:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

Apr 22, 2024, 8:45 AM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Apr 19, 2024, 5:10 PM EDT - 1 year ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

Apr 12, 2024, 8:00 AM EDT - 1 year ago

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 27, 2024, 8:07 AM EDT - 1 year ago

Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders

Mar 12, 2024, 2:34 PM EDT - 1 year ago

ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering

Feb 29, 2024, 7:00 AM EST - 1 year ago

ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

Jan 8, 2024, 6:45 AM EST - 1 year ago

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Jan 2, 2024, 7:00 AM EST - 1 year ago

ASLAN Pharmaceuticals Announces Participation in January Investor Conferences

Dec 12, 2023, 7:00 AM EST - 1 year ago

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Nov 3, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Oct 27, 2023, 8:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 18, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

Oct 13, 2023, 9:30 AM EDT - 2 years ago

ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress

Sep 22, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress

Sep 7, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 11, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 6, 2023, 8:22 AM EDT - 2 years ago

Aslan Pharmaceuticals shares slide amid new data on atopic dermatitis treatment

Jul 6, 2023, 7:55 AM EDT - 2 years ago

Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis

Jul 5, 2023, 4:30 PM EDT - 2 years ago

ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis

Jun 23, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Jun 22, 2023, 7:30 AM EDT - 2 years ago

ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

Jun 1, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Apr 28, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 28, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements

Mar 24, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 14, 2023, 7:00 AM EDT - 2 years ago

ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting

Mar 10, 2023, 7:00 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

Feb 28, 2023, 7:00 AM EST - 2 years ago

ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

Feb 24, 2023, 6:00 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M

Feb 24, 2023, 5:59 AM EST - 2 years ago

ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients

Nov 21, 2022, 7:00 AM EST - 3 years ago

ASLAN Pharmaceuticals to Participate in a Fireside Chat at 34th Annual Piper Sandler Healthcare Conference

Oct 28, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 14, 2022, 7:15 AM EDT - 3 years ago

ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Sep 13, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Announces Acceptance of Two Late-Breaking Abstracts for e-Poster Presentation at the 51st Annual European Society for Dermatological Research Meeting

Sep 7, 2022, 6:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Multiple Posters at the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress

Sep 2, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:03 AM EDT - 3 years ago

ASLAN PHARMACEUTICALS SIGNS LICENSE AGREEMENT WITH BELLE.AI TO USE BELLESTUDY™ IMAGE CAPTURE SOFTWARE IN ATOPIC DERMATITIS CLINICAL TRIALS

Aug 25, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Signs License Agreement With Belle.ai to Use belleStudy™ Image Capture Software in Atopic Dermatitis Clinical Trials

Aug 22, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals to Host a Hybrid R&D Day on September 15, 2022

Aug 12, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jun 7, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis

May 31, 2022, 7:00 AM EDT - 3 years ago

ASLAN Pharmaceuticals to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Stormra Aug. 26 at 6:02 PM

$ASLN I just got this....

1 · Reply

HPgambler Aug. 19 at 12:32 PM

1 · Reply

PLATINUM_TRADES Aug. 8 at 12:17 PM

$ASLN hello.. Anyone in here? What is going on here😑

0 · Reply

GhostAlphaTrading Jun. 17 at 12:08 PM

$ASLN Is this delisted??

1 · Reply

TrdrBuckNKy Apr. 17 at 2:05 PM

$ASLN News 15/04 08:02 ASLAN PHARMACEUTICALS LTD HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ: ASLN) with a Buy and maintains $9 price target.

1 · Reply

redfox43202 Jan. 19 at 10:36 PM

$ASLN Got charged again for ADR fees on 1/14. God damn it. What a curse to own this shit. How many times have we been charged for nothing?

0 · Reply

GhostAlphaTrading Dec. 6 at 11:22 AM

$ASLN ......can't even put a sell order in or a buy what's going on..

0 · Reply

goodetrades Nov. 19 at 2:47 PM

2 · Reply

10BillyBioBearBruiser Nov. 13 at 4:37 PM

$ASLN What a call 🫡 Well take your word for $ALT

1 · Reply

SQUEAKSBANDIT Nov. 8 at 12:56 AM

how many shares do you guys have i have 1k @ .60 $ASLN

3 · Reply

Target25UP Oct. 25 at 10:03 PM

$ASLN is this gonna be tradeable in Robinhood again ?

1 · Reply

SQUEAKSBANDIT Oct. 11 at 11:06 AM

$ASLN would it benefit us in any way to convert to ordinary shares? could they even be held in a standard us brokerage account? do the ordinaries currently trade in Singapore?

1 · Reply

redfox43202 Oct. 9 at 1:10 PM

$ASLN I got notification from Fidelity that JPM is about to liquidate ADR, we have options to convert to 200 shares to avoid that. So I contacted the liquidator about the status of the liquidation. Here is what she replied: Please be informed that we are only appointed as the liquidator for Aslan Pharmaceuticals Pte Ltd (In Creditors’ Voluntary Liquidation) (“Aslan SG”) and Quantuma is not appointed to Aslan Pharmaceuticals Limited (“Aslan KY”). However, we understand that a creditor of Aslan Pharmaceuticals Limited is in the midst of preparing a Petition to file in the Grand Court of the Cayman Islands seeking to place it into Official Liquidation. Once Aslan KY is placed into liquidation, the relevant parties will reach out to you for the next steps. Thank you. Pei Shi Foo Senior Associate Quantuma International UK | ASIA-PACIFIC | CARIBBEAN | MIDDLE EAST

3 · Reply

redfox43202 Aug. 19 at 9:08 PM

$ASLN How many times have we been charged fees in the past 6 months? My recent one was July 15. Last two charges brought my IRA to negative cash balance. Are there anymore coming?

1 · Reply